From Diagnostic Tool to Surgical Platform: The OCT Transformation
Optical coherence tomography is a high-resolution, non-invasive interferometric imaging modality capable of producing cross-sectional and three-dimensional microstructural images of biological tissue at micrometer-scale resolution. What began as a laboratory technique for retinal diagnostics has evolved—across the 2010–2026 patent filing window analysed here—into a real-time intraoperative guidance platform, with accelerating integration of artificial intelligence, augmented reality, and robotics across clinical and non-clinical verticals.
The foundational mechanism—low-coherence interferometry with a broadband or swept light source split into sample and reference arms—is common across nearly all retrieved patents. Differentiation occurs in how spectral information is decoded, how scanning is implemented (galvanometer mirrors, MEMS, fibre-based probes), and how output data is processed and displayed. According to WIPO, medical imaging remains one of the most active global patent categories, and OCT exemplifies this trend with continuous multi-jurisdictional filings across every year in this dataset.
OCT innovations in this dataset cluster around four principal technical domains: system-level optical architectures including spectral-domain (SD-OCT), swept-source (SS-OCT), and full-field OCT; intraoperative integration with surgical microscopes and AR overlays; AI and machine learning-based image processing and predictive analytics; and hardware miniaturisation toward portable and home-use devices.
OCT angiography detects blood flow via temporal decorrelation of repeat B-scans, enabling visualisation of retinal and choroidal vascular networks without contrast agents. Wide-field OCTA stitching and resolution enhancement are active areas of IP competition among multiple geographically distributed filers, including Carl Zeiss Meditec, the Chinese Academy of Sciences, and the University of Southern California.
Optical coherence tomography (OCT) is a high-resolution, non-invasive interferometric imaging modality that produces cross-sectional and three-dimensional microstructural images of biological tissue at micrometer-scale resolution, using low-coherence interferometry with a broadband or swept light source split into sample and reference arms.
Fifteen Years of OCT Patent Filings: Three Distinct Waves
The OCT patent landscape spans approximately 15 years of continuous filings from 2010 to early 2026, with a clear progression from foundational optical architecture patents through commercialisation-driven surgical guidance filings to the current frontier of robotics, AR integration, and home-use devices.
Wave 1: Optical Architecture Foundations (2010–2015)
Core signal-processing and optical architecture patents dominate the earliest window. Zhejiang University’s wide-spectrum, high-resolution spectral-domain detection method using spatiotemporal beam splitting (filed 2010–2011, CN) and the University of Texas System’s forward-imaging fibre-based OCT probe (2010, JP) represent early infrastructure filings. Carl Zeiss Meditec filed wide-field retinal OCT stitching methods in 2015 (CN), establishing foundational approaches for composite wide-FOV imaging. Doheny Eye Institute contributed OCT-based ophthalmic testing systems in 2011 (EP, US), prefiguring self-administered patient testing.
Wave 2: Commercialisation and AI Augmentation (2016–2021)
This period is characterised by rapid proliferation of intraoperative OCT systems and AI-augmented image processing. Alcon Lensx / Alcon filings for SD-OCT-guided cataract surgery (2017–2020, JP) and Novartis / Bioptigen procedural OCT methods (2016–2019, JP, EP) reflect commercialisation pressure in surgical guidance. The Medical University of Vienna’s AI prediction model for OCT tissue analysis appeared across multiple jurisdictions from 2016 (WO) through 2020 (US). Nidek Co., Ltd. filed machine-learning-based image enhancement patents from 2020–2021 (JP).
Wave 3: Robotics, AR, and Point-of-Care (2022–2026)
The most recent results signal convergence of OCT with robotics, augmented reality, and IOL adjustment. Alcon Inc. filed OCT-guided robotic ophthalmic procedure patents in 2025 (JP) and integrated visualisation + OCT system filings in 2025 (EP). Toward Pi (Beijing) Medical Technology filed intraoperative OCT navigation systems in 2026 (KR). Optos PLC filed tissue velocity processing methods for retinal OCT in 2025–2026 (JP), and Nanyang Technological University filed a dispersive-element-based wide-field OCT system for skin and retinal OCTA in 2024 (CN).
Core Engine Architectures: SD-OCT, SS-OCT, and Beyond
SD-OCT and SS-OCT represent the dominant acquisition architectures across this dataset, and understanding their technical distinctions is essential for mapping the IP landscape. SD-OCT uses a spectrometer to decode depth information in parallel; SS-OCT uses a rapidly tuned narrowband laser to encode depth as frequency over time, enabling higher acquisition speeds and longer imaging ranges.
Spectral-domain OCT (SD-OCT) decodes depth information in parallel using a spectrometer, while swept-source OCT (SS-OCT) uses a rapidly tuned narrowband laser to encode depth as frequency over time—enabling higher acquisition speeds and longer imaging ranges than SD-OCT.
Key architectural innovations in this dataset include the University of Kent’s master-slave interferometry approach (2018, JP), which enables parallel coherence gating from positive and negative optical path differences, eliminating the k-space linearisation step that adds computational overhead in conventional SD-OCT. Zhejiang University’s cascaded temporal and spatial dispersive element method (2011, CN) achieves high SNR spectral-domain detection while suppressing field curvature artefacts. At the industrial end of the spectrum, Thorlabs applied SS-OCT with MEMS-tunable VCSEL light sources to non-biological engineered objects for industrial 3D metrology at high speed and spatial resolution (2022, CN)—a direct application of OCT principles outside medicine, as documented by standards bodies including IEEE in metrology contexts.
“Robotic OCT integration represents the highest-growth white space in the current patent landscape: only a small number of filings explicitly address closed-loop OCT-to-robot coordinate mapping—an emerging domain where early patent positions may be strategically valuable.”
Carl Zeiss Meditec’s mode-switchable anterior/posterior segment imaging system (2019, JP) implements dual-mode coverage by controlling spectral bandwidth relative to the 1060 nm water absorption window—a practical solution to the longstanding challenge of covering both anterior and posterior ocular segments with a single device. The 1060 nm wavelength window is also exploited by OCT angiography systems, where anterior/posterior switching enables comprehensive retinal and corneal vascular mapping in a single clinical session.
Explore the full OCT patent dataset and identify white space in your technology area with PatSnap Eureka.
Analyse OCT Patents in PatSnap Eureka →AI-Enhanced OCT: From Noise Reduction to Predictive Disease Monitoring
Multiple assignees have filed patents on applying machine learning models—including deep neural networks and prediction models—to OCT data for noise reduction, super-resolution, disease prediction, and tissue feature extraction, making AI-enhanced OCT image processing one of the fastest-growing sub-domains in this dataset.
The Medical University of Vienna’s prediction model (2024, EP) applies a machine learning approach to retinal OCT data to generate prospective tissue feature parameters, enabling predictive monitoring of disease progression rather than purely retrospective diagnosis. This multi-jurisdictional filing portfolio—spanning WO (2016), US (2018), and EP (2024)—illustrates how a single AI-OCT concept can be prosecuted across markets over nearly a decade. Nidek Co., Ltd. takes a different approach, training a machine learning model on addition-averaged multi-frame images to generate high-quality target images from lower-quality base inputs, suppressing speckle noise without requiring paired training data of equal quality.
The Ningbo Institute of Industrial Technology (Chinese Academy of Sciences) addresses the paired training data scarcity problem in wide-area OCTA directly: its 2020 CN filing applies unpaired deep learning to translate wide-area low-resolution OCTA subimages to high-resolution equivalents. This approach—acknowledged in the broader imaging AI literature published by Nature as a key challenge in medical image super-resolution—bypasses the need for matched low/high-resolution image pairs that are difficult to acquire in clinical settings.
Multiple assignees—including the Medical University of Vienna, Nidek Co., Ltd., and the Chinese Academy of Sciences Ningbo Institute—have filed foundational machine learning prediction and super-resolution patents for OCT. Differentiating future filings will need to claim specific model architectures, training dataset constructions, or clinical-task-specific outputs rather than general AI application to OCT data.
The Medical University of Vienna has filed OCT AI prediction model patents across four jurisdictions—WO (2016), US (2018), EP (2024), and additional records—demonstrating a multi-decade prosecution strategy for a machine learning approach that generates prospective tissue feature parameters from retinal OCT data to enable predictive disease monitoring.
Application Domains: Where OCT Patent Activity Is Concentrating
Intraoperative surgical guidance—spanning cataract, glaucoma, vitreoretinal, and IOL adjustment procedures—represents the largest and most commercially active cluster in this dataset, with ophthalmic diagnostics forming a closely related but distinct second cluster.
Intraoperative Surgical Guidance
The intraoperative OCT cluster is anchored by Alcon’s comprehensive portfolio. Alcon Lensx’s SD-OCT-guided laser fragmentation system for cataract surgery (2017, JP) and Novartis’s real-time surgical instrument tracking system (2020, JP)—which enables beam scanner redirection to follow intraocular instruments in real time—represent the commercialisation layer. Bioptigen’s procedural OCT system (2019, EP) describes a complete intraoperative workflow: subject orientation, structural baseline construction, clinical parameter computation, and iterative plan modification anchored by OCT feedback. The Suzhou Institute of Biomedical Engineering (Chinese Academy of Sciences) fuses 2D microscope video and 3D OCT volumes using synchronised guide illumination, enabling real-time AR overlay during microsurgery (2023, JP).
Michael S. Berlin’s portfolio of approximately 6–7 records across JP and KR jurisdictions specifically targets OCT-guided glaucoma surgery—trabecular meshwork targeting and Schlemm’s canal access—representing one of the most focused single-inventor portfolios in this dataset. Alcon’s 2025 JP filing extends intraoperative OCT to post-implant refractive adjustment of intraocular lenses, a procedure that previously relied on subjective refraction rather than objective tissue measurement.
Map freedom-to-operate risk across Alcon’s intraoperative OCT portfolio with PatSnap Eureka’s AI-powered patent analysis.
Explore Full Patent Data in PatSnap Eureka →Ophthalmic Diagnostics
The diagnostic cluster features filings from Nidek Co., Ltd., Canon Inc., Topcon Corp., and Carl Zeiss Meditec addressing retinal OCT follow-up protocols, wide-field fundus mapping, OCTA for vascular network visualisation, and multi-visit scan alignment. Nidek’s ophthalmologic information analysis device (2024, JP) enables cross-visit scan range reconciliation for longitudinal disease monitoring—a practical solution to the clinical problem of ensuring comparable scan coverage across appointments separated by months or years. The University of Tsukuba’s OCT-based choroid vascular plexus quantification filing (2015, JP) reflects enduring interest in deep retinal layer characterisation as a biomarker for systemic disease.
Cardiovascular and Industrial Applications
Beyond ophthalmology, intravascular OCT (IVOCT) for coronary imaging appears across Korean filings. Keimyung University’s AI-based computer-aided diagnosis system (2021, KR) performs automatic vessel lumen detection, shape feature extraction, and normal/abnormal lumen classification from OCT medical images. A 2025 Korean filing uses AI models to identify bifurcation points in intravascular OCT image sequences—directly relevant to stent placement planning. In the non-medical domain, Thorlabs’ SS-OCT coordinate measurement machine system (2022, CN) repurposes OCT for high-speed non-contact 3D digitisation of engineered objects, replacing mechanical CMM probes with reconfigurable optical probes. Nanyang Technological University’s 2024 CN filing explicitly demonstrates in vivo human skin OCTA imaging, generating wide-field vascular network maps of the skin using a dispersive-element scanning approach.
Japan (JP) dominates the OCT patent dataset by filing volume, reflecting the strategy of major ophthalmic and precision optics companies—including Alcon, Novartis, Carl Zeiss Meditec, Nidek, Topcon, and Canon—filing in Japan as a key commercial market. China (CN) is the second most represented jurisdiction, with Korea (KR) featuring strongly in surgical guidance and AI-based intravascular OCT.
Emerging Directions and Strategic White Space in OCT Innovation
The most recent filings in this dataset (2024–2026) reveal five forward-looking trajectories that define where the next wave of OCT IP competition will be fought—and where white space remains for new entrants.
1. OCT-Guided Robotics
Alcon’s 2025 JP filing on OCT-guided robotic ophthalmic procedures uses multi-galvanometer absolute/incremental encoder data to map OCT-derived tissue positions into the robot’s 3D coordinate system, enabling submillimeter-precision autonomous or assisted instrument placement. Toward Pi (Beijing)’s 2026 KR filing pursues real-time 3D OCT navigation tied to galvanometer scanners. Only a small number of filings in this dataset explicitly address closed-loop OCT-to-robot coordinate mapping—representing an emerging domain where early patent positions may be strategically valuable, particularly for instrument tracking and autonomous surgical motion control. The broader trajectory aligns with surgical robotics research documented by NIH-funded programmes targeting submillimetre precision in ophthalmic microsurgery.
2. Integrated Stereoscopic Volumetric Visualisation
Alcon’s 2025 EP filing integrates an OCT module and stereoscopic visualisation camera in a single head unit, registering volumetric OCT and stereo camera data to produce a composite shared view of the surgical target. A companion calibration system (CN, 2025) shows convergence of stereoscopic camera and OCT into a single registered volumetric output, eliminating the traditional separation between surgical visualisation and depth imaging.
3. Tissue Velocity and Phase Analysis
Optos PLC’s JP filings (2026 and 2025) introduce per-voxel tissue velocity indexing from phase information in sequential OCT image sets—a functional extension of structural OCT toward quantitative biomechanics. This approach moves OCT beyond morphological imaging toward dynamic tissue characterisation, opening potential applications in retinal biomechanics research.
4. Anterior Segment Geometry and Glaucoma Screening
Optos’ 2026 JP filing targets automated scleral spur localisation in anterior segment OCT for geometric angle measurement, directly relevant to glaucoma screening. This automated geometry extraction approach reduces dependence on manual annotation by clinicians, potentially enabling population-scale screening workflows.
5. Home-Based and Patient-Operated OCT
Acucela Inc.’s dual JP filings (2023, 2025) describe a compact, drop-resistant, self-administered OCT device for at-home retinal thickness monitoring by patients without clinical assistance. With Acucela and Doheny Eye Institute both filing patient-operated OCT systems, the transition from clinic-bound to patient-administered monitoring is technically documented. Regulatory pathway, miniaturisation cost, and patient adherence—not IP landscape density—are identified as the primary barriers to entry in this segment. This trajectory aligns with the broader telemedicine expansion tracked by global health organisations including the WHO in chronic disease management programmes.